dromlakhani Suggest cessation of testosterone if no response by 6 months
STEP 1 — Gather Information
Confirm diagnosis of HSDD, verify testosterone preparation and dose, assess treatment adherence, and document baseline and current levels of sexual desire and satisfaction (e.g., via patient-reported outcome). Ensure at least 6 months have elapsed since therapy initiation.
STEP 2 — Rule In / Rule Out
If the woman has completed ≥6 months of testosterone therapy and reports no improvement in desire or sexual satisfaction, proceed to consider cessation; if any improvement is noted, continue therapy and schedule routine monitoring.
STEP 3 — Classify or Stratify
Classify the patient as a non‑responder to testosterone therapy based on lack of symptomatic improvement after 6 months, and screen for signs of androgen excess (acne, hirsutism, voice changes) or adverse events that might affect the decision to stop.
STEP 4 — Decide
Discontinue testosterone therapy, discuss alternative non‑hormonal management strategies for HSDD (e.g., psychosocial counseling, sex therapy), and arrange follow‑up in 4–6 weeks to evaluate symptom changes and address any withdrawal concerns.
Clinical Guardrails / Mimics / Pitfalls
Do not stop therapy before the 6‑month mark without verifying non‑adherence; avoid continuing ineffective therapy beyond 6 months due to potential androgenic side effects and lack of long‑term safety data; do not attribute lack of response to non‑adherence without confirming proper patch/gel use; monitor for recurrence of symptoms after cessation and consider re‑evaluation if symptoms worsen.
Concrete Clinical Example
A 55‑year‑old postmenopausal woman with HSDD used a 300 µg/d transdermal testosterone patch for 6 months. At follow‑up she reports no change in sexual desire or satisfaction, confirms proper patch application. Clinician discontinues the patch, initiates referral for cognitive‑behavioral sex therapy, and schedules a revisit in 1 month.
Source: Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2260